NASDAQ:PAVM PAVmed (PAVM) Stock Price, News & Analysis → Log Into Marc's $5,000 System Today (From Chaikin Analytics) (Ad) Free PAVM Stock Alerts $1.57 -0.16 (-9.25%) (As of 04:00 PM ET) Add Compare Share Share Today's Range$1.57▼$1.6950-Day Range$1.65▼$2.7352-Week Range$1.57▼$9.00Volume94,720 shsAverage Volume65,006 shsMarket Capitalization$14.81 millionP/E RatioN/ADividend YieldN/APrice Target$21.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get PAVmed alerts: Email Address PAVmed MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,188.3% Upside$21.00 Price TargetShort InterestN/ADividend StrengthN/ASustainability-0.78Upright™ Environmental ScoreNews Sentiment0.44Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.77 out of 5 starsMedical Sector725th out of 931 stocksSurgical & Medical Instruments Industry83rd out of 101 stocks 3.5 Analyst's Opinion Consensus RatingPAVmed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoveragePAVmed has only been the subject of 1 research reports in the past 90 days.Read more about PAVmed's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for PAVM. Previous Next 0.0 Dividend Strength Dividend YieldPAVmed does not currently pay a dividend.Dividend GrowthPAVmed does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePAVmed has received a 63.96% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Medical devices engineering", "Intravenous therapy equipment", and "Biopsy systems" products. See details.Environmental SustainabilityThe Environmental Impact score for PAVmed is -0.78. Previous Next 1.9 News and Social Media Coverage News SentimentPAVmed has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for PAVmed this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added PAVmed to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PAVmed insiders have not sold or bought any company stock.Percentage Held by Insiders12.60% of the stock of PAVmed is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 19.93% of the stock of PAVmed is held by institutions.Read more about PAVmed's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of PAVmed is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PAVmed is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about PAVmed's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Chaikin AnalyticsLog Into Marc's $5,000 System TodayNew Panic Could Sweep America Mark these words in 2024. Everyone's going to cash… Wall Street legend says: "A little-known vehicle outside of banks could double… triple… or even quadruple your life savings if you know where to find it right now." We urge you to move your cash into this vehicle in 2024. More here. About PAVmed Stock (NASDAQ:PAVM)PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.Read More PAVM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PAVM Stock News HeadlinesMay 20, 2024 | americanbankingnews.comFY2024 Earnings Forecast for PAVmed Inc. Issued By Cantor Fitzgerald (NASDAQ:PAVM)May 18, 2024 | finanznachrichten.dePAVmed Inc.: PAVmed Provides Business Update and First Quarter 2024 Financial ResultsMay 15, 2024 | finance.yahoo.comPAVmed Inc (PAVM) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth and Financial ...May 13, 2024 | prnewswire.comPAVmed Provides Business Update and First Quarter 2024 Financial ResultsMay 9, 2024 | finance.yahoo.comLegacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA RecallMay 7, 2024 | prnewswire.comLucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of DirectorsMay 3, 2024 | prnewswire.comPAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024May 2, 2024 | finance.yahoo.comLucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024May 2, 2024 | prnewswire.comLucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer TestingMay 1, 2024 | finance.yahoo.comVeris teams up with Ohio University for cancer digital health pilotApril 30, 2024 | prnewswire.comPAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research InstituteApril 29, 2024 | finance.yahoo.comInnovations in Cardiac Care: The Future of Cardiac Ablation Devices RevealedApril 29, 2024 | prnewswire.comLucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness MonthApril 17, 2024 | msn.comPAVmed (PAVM) Price Target Decreased by 8.51% to 10.97April 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for PAVmed on Growth and Valuation Prospects Amidst Product CommercializationMarch 29, 2024 | seekingalpha.comPAVmed Inc. (PAVM) Q4 2023 Earnings Call TranscriptMarch 29, 2024 | markets.businessinsider.comBuy Rating Affirmed for PAVmed with Strategic Focus on Lucid Diagnostics and Veris Cancer Care Amid Adjusted Price TargetMarch 28, 2024 | finance.yahoo.comQ4 2023 PAVmed Inc Earnings CallMarch 27, 2024 | finance.yahoo.comPAVmed Full Year 2023 Earnings: EPS Beats ExpectationsMarch 26, 2024 | prnewswire.comPAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial ResultsMarch 25, 2024 | markets.businessinsider.comWhat Wall Street expects from PAVmed's earningsMarch 25, 2024 | tmcnet.comNovosound secures patent for wireless wearable ultrasound imaging platformMarch 21, 2024 | prnewswire.comLucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening PopulationMarch 21, 2024 | prnewswire.comPAVmed Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpXMarch 13, 2024 | prnewswire.comPAVmed to Hold a Business Update Conference Call and Webcast on March 27, 2024See More Headlines Receive PAVM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PAVmed and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/26/2024Today5/28/2024Next Earnings (Estimated)8/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:PAVM CUSIPN/A CIK1624326 Webwww.pavmed.com Phone(212) 949-4319FaxN/AEmployees107Year FoundedN/APrice Target and Rating Average Stock Price Target$21.00 High Stock Price Target$21.00 Low Stock Price Target$21.00 Potential Upside/Downside+1,188.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($9.0978) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-64,180,000.00 Net Margins-2,037.67% Pretax Margin-2,505.34% Return on EquityN/A Return on Assets-99.19% Debt Debt-to-Equity RatioN/A Current Ratio0.54 Quick Ratio0.53 Sales & Book Value Annual Sales$2.45 million Price / Sales6.27 Cash FlowN/A Price / Cash FlowN/A Book Value($3.35) per share Price / Book-0.49Miscellaneous Outstanding Shares9,430,000Free Float8,244,000Market Cap$15.37 million OptionableOptionable Beta0.83 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Lishan Aklog M.D. (Age 58)Chairman & CEO Comp: $953.2kMr. Dennis M. McGrath CPA (Age 67)President & CFO Comp: $673.5kMr. Shaun M. O'Neill M.B.A. (Age 41)Executive VP & COO Comp: $498kMr. Michael Adam Gordon (Age 49)Executive VP, General Counsel & Secretary Comp: $710.5kDr. Brian J. deGuzman M.D. (Age 59)Executive VP, Chief Technology & Compliance Officer Comp: $427.6kDr. Suman M. Verma M.D.Ph.D., Senior VP of Molecular Genetics & Chief Scientific OfficerMichael ParksVice President of Investor RelationsDr. Deepika A. Lakhani Ph.D.Senior VP, Chief Regulatory & Quality OfficerDr. Victoria T. Lee M.D.Senior VP & Chief Medical OfficerMore ExecutivesKey CompetitorsMeihua International Medical TechnologiesNASDAQ:MHUAMicrobot MedicalNASDAQ:MBOTNEXGELNASDAQ:NXGLSTRATA Skin SciencesNASDAQ:SSKNLyra TherapeuticsNASDAQ:LYRAView All Competitors PAVM Stock Analysis - Frequently Asked Questions Should I buy or sell PAVmed stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PAVmed in the last twelve months. There are currently 1 hold rating and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PAVM shares. View PAVM analyst ratings or view top-rated stocks. What is PAVmed's stock price target for 2024? 2 Wall Street research analysts have issued 1-year price targets for PAVmed's shares. Their PAVM share price targets range from $21.00 to $21.00. On average, they anticipate the company's stock price to reach $21.00 in the next year. This suggests a possible upside of 1,188.3% from the stock's current price. View analysts price targets for PAVM or view top-rated stocks among Wall Street analysts. How have PAVM shares performed in 2024? PAVmed's stock was trading at $4.12 at the beginning of 2024. Since then, PAVM stock has decreased by 60.4% and is now trading at $1.63. View the best growth stocks for 2024 here. When is PAVmed's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 20th 2024. View our PAVM earnings forecast. How were PAVmed's earnings last quarter? PAVmed Inc. (NASDAQ:PAVM) posted its quarterly earnings data on Tuesday, March, 26th. The company reported ($1.57) earnings per share (EPS) for the quarter. The company had revenue of $1.05 million for the quarter. When did PAVmed's stock split? Shares of PAVmed reverse split on the morning of Thursday, December 7th 2023. The 1-15 reverse split was announced on Thursday, December 7th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of PAVmed own? Based on aggregate information from My MarketBeat watchlists, some companies that other PAVmed investors own include Tonix Pharmaceuticals (TNXP), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Co-Diagnostics (CODX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Cidara Therapeutics (CDTX), Catalyst Pharmaceuticals (CPRX), Onconova Therapeutics (ONTX) and Strongbridge Biopharma (SBBP). How do I buy shares of PAVmed? Shares of PAVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PAVM) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaDigitizing the $11T commodities sector with one tiny stockResource Stock DigestBiggest Prediction of My 50-Year Career on Wall StreetChaikin AnalyticsIs Artificial Intelligence the Biggest Bubble in History?InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap Profits41 banks launch ‘crypto dollar’Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PAVmed Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
